Floatz logo

Panax Ginseng

Schizoaffective Disorder

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Schizoaffective Disorder cohort.

Asset / SponsorPhaseRating
Paliperidone Palmitate 3-Month Formulation
Luye Pharma Group Ltd.
Phase 4BBB
Seroquel®
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 4BBB
Lurasidone
University of Texas Southwestern Medical Center
Phase 4BBB
Bxcl501
BioXcel Therapeutics Inc
Phase 4BBB
Olanzapine
The Royal Ottawa Mental Health Centre
Phase 4BBB

View all 50 →

Same molecule, other indications

Panax Ginseng is also rated in:

tardive dyskinesiaDormant
CCC
Indicative ·
52 / 100
View asset →
cancerDormant
CCC
Indicative ·
48 / 100
View asset →
Alzheimer diseaseDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →